Lilly(Eli) & Co (NYSE: LLY) has a higher price-to-earnings ratio of 68.05x compared to its average ratio, The 36-month beta value for LLY is at 0.48. Analysts have varying views on the stock, with 16 analysts rating it as a “buy,” 8 rating it as “overweight,” 3 as “hold,” and 1 as “sell.”
The public float for LLY is 849.99M, and currently, shorts hold a 0.76% of that float. The average trading volume for LLY on May 06, 2025 was 3.88M shares.
LLY) stock’s latest price update
Lilly(Eli) & Co (NYSE: LLY)’s stock price has dropped by -0.26 in relation to previous closing price of 823.62. Nevertheless, the company has seen a loss of -6.36% in its stock price over the last five trading days. cnbc.com reported 2025-05-05 that President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump’s planned tariffs on pharmaceuticals imported into the U.S.
LLY’s Market Performance
Lilly(Eli) & Co (LLY) has seen a -6.36% fall in stock performance for the week, with a 4.10% gain in the past month and a 1.36% surge in the past quarter. The volatility ratio for the week is 3.40%, and the volatility levels for the past 30 days are at 4.41% for LLY. The simple moving average for the past 20 days is 2.28% for LLY’s stock, with a -2.54% simple moving average for the past 200 days.
Analysts’ Opinion of LLY
Many brokerage firms have already submitted their reports for LLY stocks, with HSBC Securities repeating the rating for LLY by listing it as a “Reduce.” The predicted price for LLY in the upcoming period, according to HSBC Securities is $700 based on the research report published on April 28, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see LLY reach a price target of $975. The rating they have provided for LLY stocks is “Overweight” according to the report published on April 22nd, 2025.
BofA Securities gave a rating of “Buy” to LLY, setting the target price at $997 in the report published on December 10th of the previous year.
LLY Trading at -1.17% from the 50-Day Moving Average
After a stumble in the market that brought LLY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.53% of loss for the given period.
Volatility was left at 4.41%, however, over the last 30 days, the volatility rate increased by 3.40%, as shares surge +11.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.98% lower at present.
During the last 5 trading sessions, LLY fell by -6.36%, which changed the moving average for the period of 200-days by -9.29% in comparison to the 20-day moving average, which settled at $803.16. In addition, Lilly(Eli) & Co saw 6.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LLY starting from DONALD ZAKROWSKI, who proposed sale 2,000 shares at the price of $821.86 back on Mar 13 ’25. After this action, DONALD ZAKROWSKI now owns shares of Lilly(Eli) & Co, valued at $1,643,720 using the latest closing price.
Zakrowski Donald A, the SVP, Finance, & CAO of Lilly(Eli) & Co, sale 1,000 shares at $818.24 during a trade that took place back on Mar 13 ’25, which means that Zakrowski Donald A is holding 5,840 shares at $818,240 based on the most recent closing price.
Stock Fundamentals for LLY
Current profitability levels for the company are sitting at:
- 0.41 for the present operating margin
- 0.82 for the gross margin
The net margin for Lilly(Eli) & Co stands at 0.23. The total capital return value is set at 0.34. Equity return is now at value 77.73, with 14.49 for asset returns.
Based on Lilly(Eli) & Co (LLY), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at 0.24. The debt to equity ratio resting at 2.44. The interest coverage ratio of the stock is 33.76.
Currently, EBITDA for the company is 15.23 billion with net debt to EBITDA at 2.12. When we switch over and look at the enterprise to sales, we see a ratio of 16.61. The receivables turnover for the company is 3.5for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In conclusion, Lilly(Eli) & Co (LLY) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
